Related Experiment Videos
Hematologic toxicity from penicillamine in rheumatoid arthritis
The Journal of Rheumatology. Supplement
|January 1, 1981
Summary
Penicillamine treatment for rheumatoid arthritis can cause low platelet counts (thrombocytopenia) and low white blood cell counts (leukopenia). Frequent monitoring is crucial to manage these potentially serious side effects.
Area of Science:
- Rheumatology
- Hematology
- Pharmacology
Background:
- Penicillamine is used to treat rheumatoid arthritis.
- Adverse hematologic effects, including thrombocytopenia and leukopenia, are known complications of penicillamine therapy.
- Isolated cases of polycythemia have also been reported.
Purpose of the Study:
- To summarize the incidence and characteristics of hematologic side effects associated with penicillamine treatment.
- To emphasize the importance of monitoring patients receiving penicillamine.
Main Methods:
- Review of existing literature on penicillamine-induced hematologic adverse events.
- Analysis of reported cases of thrombocytopenia, leukopenia, and polycythemia.
Main Results:
- Thrombocytopenia occurs in approximately 8% of rheumatoid arthritis patients on penicillamine and is typically reversible.
- Leukopenia and bone marrow aplasia are rare but can be sudden in onset.
- Polycythemia is an infrequent finding.
Conclusions:
- Close monitoring of patients undergoing penicillamine treatment is essential.
- Early detection and management of hematologic abnormalities can prevent severe outcomes.
- Awareness of these potential side effects is critical for clinicians.